Walker M J, Rohde M, Wehland J, Timmis K N
Department of Microbiology, GBF-National Research Centre for Biotechnology, Braunschweig, Germany.
Infect Immun. 1991 Nov;59(11):4238-48. doi: 10.1128/iai.59.11.4238-4248.1991.
Appropriately detoxified pertussis toxin (PT) of Bordetella pertussis is considered to be an essential component of new-generation whooping cough vaccines, but the development of a procedure to obtain high levels of purified toxin has been and continues to be a major difficulty. To produce a system enabling the biological separation of PT from other virulence determinants of B. pertussis and the attainment of high yields of the toxin, minitransposons containing the PT operon were constructed and stably integrated into the chromosome of Bordetella virulence regulatory gene (bvg)-negative Bordetella bronchiseptica ATCC 10580. Since the minitransposons introduced into Bordetella spp. lack the cognate transposase function, they are unable to undergo further transposition events or mediate gene deletions and rearrangements that lead to strain instability. The TnPtacPT minitransposon contains the PT operon under the control of the tac promoter and directs IPTG (isopropyl-beta-D-thiogalactopyranoside)-inducible expression of PT in B. bronchiseptica ATCC 10580. The level of IPTG-induced PT expression was, however, lower than that found for the wild-type B. pertussis Tohama I strain. The TnfusPT minitransposon contains a promoterless PT operon which is only expressed after insertion of the transposon downstream of an appropriately oriented indigenous promoter. After "promoter probing" of B. bronchiseptica with the transposon, clones were screened for PT production by immunoblotting with specific monoclonal antibodies. One clone, designated B. bronchiseptica 10580:: TnfusPT1, expresses significantly higher levels of PT than does B. pertussis Tohama I. The recombinant toxin produced was biologically active in the Chinese hamster ovary cell-clustering assay. High-level expression of PT from a B. bronchiseptica host promoter should provide better yields of the toxin from bacteria not producing other bvg-regulated pathogenesis factors that may play a role in the undesired side effects of current pertussis vaccine preparations.
百日咳博德特氏菌经适当解毒的百日咳毒素(PT)被认为是新一代百日咳疫苗的重要组成部分,但开发一种获得高纯度毒素的方法一直是且仍然是一个主要难题。为了构建一个能够从百日咳博德特氏菌的其他毒力决定因素中生物分离PT并获得高产毒素的系统,构建了含有PT操纵子的微型转座子,并将其稳定整合到支气管败血博德特氏菌毒力调节基因(bvg)阴性的支气管败血博德特氏菌ATCC 10580的染色体中。由于引入博德特氏菌属的微型转座子缺乏同源转座酶功能,它们无法进行进一步的转座事件或介导导致菌株不稳定的基因缺失和重排。TnPtacPT微型转座子包含在tac启动子控制下的PT操纵子,并指导IPTG(异丙基-β-D-硫代半乳糖苷)诱导的PT在支气管败血博德特氏菌ATCC 10580中的表达。然而,IPTG诱导的PT表达水平低于野生型百日咳博德特氏菌Tohama I菌株。TnfusPT微型转座子包含一个无启动子的PT操纵子,该操纵子仅在转座子插入适当方向的内源启动子下游后才表达。用该转座子对支气管败血博德特氏菌进行“启动子探测”后,通过用特异性单克隆抗体进行免疫印迹筛选PT产生的克隆。一个克隆,命名为支气管败血博德特氏菌10580::TnfusPT1,表达的PT水平明显高于百日咳博德特氏菌Tohama I。产生的重组毒素在中国仓鼠卵巢细胞聚集试验中具有生物活性。来自支气管败血博德特氏菌宿主启动子的PT的高水平表达应该能从不产生其他可能在当前百日咳疫苗制剂的不良副作用中起作用的bvg调节的致病因子的细菌中获得更高产量的毒素。